HIV belly fat targeted by diabetes drug in new trial
NCT ID NCT04019197
First seen Feb 20, 2026 · Last updated May 20, 2026 · Updated 10 times
Summary
This study tests if semaglutide, a drug used for diabetes, can reduce harmful belly fat and improve heart health in people with HIV who have extra belly fat. About 108 participants will receive either the drug or a placebo for 32 weeks. The goal is to see if the drug can lower fat around organs and reduce inflammation, which may lower heart disease risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
Conditions
Explore the condition pages connected to this study.